ERAS
Price
$1.85
Change
-$0.01 (-0.54%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
523.05M
61 days until earnings call
INZY
Price
$1.35
Change
-$0.00 (-0.00%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
87.37M
61 days until earnings call
Ad is loading...

ERAS vs INZY

Header iconERAS vs INZY Comparison
Open Charts ERAS vs INZYBanner chart's image
Erasca
Price$1.85
Change-$0.01 (-0.54%)
Volume$54.69K
Capitalization523.05M
Inozyme Pharma
Price$1.35
Change-$0.00 (-0.00%)
Volume$28.68K
Capitalization87.37M
ERAS vs INZY Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. INZY commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and INZY is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (ERAS: $1.85 vs. INZY: $1.36)
Brand notoriety: ERAS and INZY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 101% vs. INZY: 169%
Market capitalization -- ERAS: $523.05M vs. INZY: $87.37M
ERAS [@Biotechnology] is valued at $523.05M. INZY’s [@Biotechnology] market capitalization is $87.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileINZY’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • INZY’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than INZY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while INZY’s TA Score has 1 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 4 bearish.
  • INZY’s TA Score: 1 bullish, 2 bearish.
According to our system of comparison, both ERAS and INZY are a bad buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а -21.78% price change this week, while INZY (@Biotechnology) price change was -31.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

ERAS is expected to report earnings on May 08, 2025.

INZY is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($523M) has a higher market cap than INZY($87.4M). ERAS YTD gains are higher at: -26.295 vs. INZY (-50.903). INZY has higher annual earnings (EBITDA): -90.3M vs. ERAS (-151.33M). ERAS has more cash in the bank: 319M vs. INZY (132M). INZY has less debt than ERAS: INZY (46.8M) vs ERAS (52.9M). ERAS (0) and INZY (0) have equivalent revenues.
ERASINZYERAS / INZY
Capitalization523M87.4M598%
EBITDA-151.33M-90.3M168%
Gain YTD-26.295-50.90352%
P/E RatioN/AN/A-
Revenue00-
Total Cash319M132M242%
Total Debt52.9M46.8M113%
TECHNICAL ANALYSIS
Technical Analysis
ERASINZY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
85%
N/A
Momentum
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
88%
MACD
ODDS (%)
Bullish Trend 11 days ago
89%
N/A
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 11 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
86%
Advances
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 16 days ago
86%
Declines
ODDS (%)
Bearish Trend about 1 month ago
86%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SACVX33.820.35
+1.05%
Spirit of America Large Cap Value C
RYMIX52.120.50
+0.97%
Rydex Telecommunications Inv
EQNVX21.830.12
+0.55%
MFS Equity Income R6
MEMHX32.750.14
+0.43%
MFS Emerging Markets Equity R4
CDWAX10.670.03
+0.28%
American Funds Dvlpg Wld Gr&Inc 529A

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.54%
XNCR - ERAS
52%
Loosely correlated
-3.94%
KYMR - ERAS
48%
Loosely correlated
+0.79%
INZY - ERAS
46%
Loosely correlated
N/A
PLRX - ERAS
46%
Loosely correlated
-3.36%
BEAM - ERAS
46%
Loosely correlated
+0.17%
More

INZY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INZY has been loosely correlated with IGMS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if INZY jumps, then IGMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INZY
1D Price
Change %
INZY100%
N/A
IGMS - INZY
52%
Loosely correlated
-3.28%
BEAM - INZY
50%
Loosely correlated
+0.17%
NTLA - INZY
47%
Loosely correlated
+0.85%
THRD - INZY
47%
Loosely correlated
+1.94%
ERAS - INZY
46%
Loosely correlated
-0.54%
More